100 related articles for article (PubMed ID: 22632362)
1. Ethnic differences in the clinical presentation of Graves' ophthalmopathy.
Chng CL; Seah LL; Khoo DH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):249-58. PubMed ID: 22632362
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of Graves' ophthalmopathy.
Stiebel-Kalish H; Robenshtok E; Gaton DD
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Graves' orbitopathy.
Dolman PJ
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):229-48. PubMed ID: 22632361
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?
Bednarczuk T; Gopinath B; Ploski R; Wall JR
Clin Endocrinol (Oxf); 2007 Jul; 67(1):3-19. PubMed ID: 17521325
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
6. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients.
Esteghamati A; Khalilzadeh O; Mobarra Z; Anvari M; Tahvildari M; Amiri HM; Rashidi A; Solgi G; Parivar K; Nikbin B; Amirzargar A
Eur J Intern Med; 2009 Jul; 20(4):424-8. PubMed ID: 19524188
[TBL] [Abstract][Full Text] [Related]
7. Pretibial myxedema is associated with polymorphism in exon 1 of CTLA-4 gene in patients with Graves' ophthalmopathy.
Khalilzadeh O; Mojazi Amiri H; Tahvildari M; Anvari M; Esteghamati A; Mobarra Z; Tehranchinia Z; Rashidi A; Amirzargar A
Arch Dermatol Res; 2009 Oct; 301(10):719-23. PubMed ID: 19037649
[TBL] [Abstract][Full Text] [Related]
8. Pediatric aspects in Graves' orbitopathy.
Gogakos AI; Boboridis K; Krassas GE
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():234-44. PubMed ID: 20467370
[TBL] [Abstract][Full Text] [Related]
9. [Graves' orbitopathy].
Eckstein A; Esser J
Klin Monbl Augenheilkd; 2011 May; 228(5):432-8. PubMed ID: 21534176
[TBL] [Abstract][Full Text] [Related]
10. [Graves' ophthalmopathy].
Badelon I; Morax S
Rev Prat; 2005 Jan; 55(2):183-6. PubMed ID: 15826000
[TBL] [Abstract][Full Text] [Related]
11. Treating the thyroid in the presence of Graves' ophthalmopathy.
Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
[TBL] [Abstract][Full Text] [Related]
12. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
[TBL] [Abstract][Full Text] [Related]
13. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
14. [Clinical manifestations of thyroid ophthalmopathy].
Fernández Hermida RV; Pinar S; Muruzábal N
An Sist Sanit Navar; 2008; 31 Suppl 3():45-56. PubMed ID: 19169294
[TBL] [Abstract][Full Text] [Related]
15. The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).
Alevizaki M; Mantzou E; Cimponeriu A; Saltiki K; Philippou G; Wiersinga W
Clin Endocrinol (Oxf); 2009 Mar; 70(3):464-8. PubMed ID: 18624999
[TBL] [Abstract][Full Text] [Related]
16. Graves' ophthalmopathy: epidemiology and natural history.
Hiromatsu Y; Eguchi H; Tani J; Kasaoka M; Teshima Y
Intern Med; 2014; 53(5):353-60. PubMed ID: 24583420
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment of Graves' ophthalmopathy.
Eckstein A; Schittkowski M; Esser J
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):339-58. PubMed ID: 22632370
[TBL] [Abstract][Full Text] [Related]
18. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.
Eckstein AK; Lösch C; Glowacka D; Schott M; Mann K; Esser J; Morgenthaler NG
Br J Ophthalmol; 2009 Aug; 93(8):1052-6. PubMed ID: 19221109
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in Graves' ophthalmopathy.
Wiersinga WM
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
